Protected PCI Patient Selection Tool

Is Your Patient Appropriate for Protected PCI?

Use the following form to determine if a patient may be appropriate to receive a Protected PCI procedure. The criteria for selection is based on U.S. FDA safety and efficacy labeling, randomized control trials, society guidelines and consensus documents made available following the completion of the form.

Results

 

 

Are any of the following conditions present in the patient?

Is evidence of severe coronary artery disease present in the patient?
Are any of the procedure based risks present in the patient?
Are any of the hemodynamic risks present in the patient?
Are any of the co-morbidities present in the patient?

Are any of the following surgical risks associated with the patient?

Are any of the following contraindications present in the patient?

 

This information is provided for educational purposes only and does not constitute medical advice. Please follow the protocols established by your center. If you have any questions, please contact Abiomed’s Clinical Support Center at 1-800-422-8666.

 

Available Resources

Guideline supported use from 2014 AHA/ACC & 2015 SCAI/ACC/HFSA/STS consensus on high-risk PCI 9,10

PROTECT II randomized controlled trial demonstrated reduced MACCE and improved LVEF 1,11

First of its kind and only PMA Approval for a hemodynamic support device in the HRPCI setting

Use in appropriate patients reimbursed by dedicated codes by Centers for Medicare and Medicaid (CMS) and all major health providers 12

Cost-effectiveness in HRPCI based on reduced: cost, length of stay, and readmissions 13,14

The Advisory Board (Optum), Cardiovascular Roundtable, publications on best practices

 

References

  1. O’Neill WW, Kleiman NS, Moses J, et al. Circulation. 2012; 126(14):1717-27.
  2. Kovacic JC, Kini A, Banerjee S, et al. J Interv Cardiol. 2015; 28(1):32-40.
  3. Cohen MG, Ghatak A, Kleiman NS, et al. Catheter Cardiovasc Interv. 2014;83(7):1057-64.
  4. Tsai TT, Stanislawski MA, Shunk KA, et al. JACC Cardiovasc Interv. 2017;10(9):866-875.
  5. Patel MR, Dehmer GJ, Hirshfeld JW, et al. J Am Coll Cardiol. 2012;59(9): 857-881.
  6. Alasnag MA, Gardi DO, Elder M, et al. Cardiovasc Revasc Med. 2011;12(5):299-303.
  7. Sjauw KD, Konorza T, Erbel R, et al. J Am Coll Cardiol. 2009;54(25):2430-2434.
  8. Levine GN, Bates ER, Blankenship JC, et al. J Am Coll Cardiol. 2011;58(24):e44-122.
  9. Amsterdam EA, Wenger NK, Brindis RG, et al. Circulation. 2014;130(25):e344-e426.
  10. Rihal CS, Naidu SS, Givertz MM, et al. J Am Coll Cardiol. 2015; 65(19):e7-e26.
  11. Dangas GD, Kini AS, Sharma SK, et al. Am J Cardiol. 2014;113(2):222-228.
  12. American Hospital Association (AHA) & Centers for Medicare & Medicaid (CMS) 2016 Hospital Coding Guidance.
  13. Gregory D, Scotti DJ, de Lissovoy G, et al. Am Health Drug Benefits. 2013;6(2):88-99.
  14. Maini B, Naidu SS, Mulukutla S, et al. Catheter Cardiovasc Interv. 2012; 80(5):717-25.

NPS-1575